< Back to previous page
Researcher
Chris Verslype
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From22 May 2017 → Today - Hepatology (Division)
Member
From1 Oct 2002 → 21 May 2017
Projects
1 - 10 of 14
- Impact of ccfDNA on clinical decision making in NEN patientsFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPTFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- [18F]AlF-NOTA-octreotide PET imaging of the somatostatin receptor in neuroendocrine tumors: comparison with [68Ga]Ga-DOTATATE and evaluation of routine clinical use.From3 Oct 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- robotiC gUided canceR nanomedicinE (CURE)From1 Oct 2021 → TodayFunding: BOF - projects
- New Strategies in Locoregional, Minimally Invasive Therapy of Liver CancerFrom1 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- The search for biomarkers in systemic treatment of advanced hepatocellular carcinoma.From1 Oct 2019 → TodayFunding: FWO Strategic Basic Research Grant
- Methylome analysis in circulating tumor DNA to predict baseline or aquired sorafenib resistance in hepatocellular carcinoma patientsFrom1 Jan 2019 → 31 Dec 2022Funding: Foundations, funds and other with scientific goal
- Daphnia: from ecological to biomedical microbiome model in the context of hypoxiaFrom1 Sep 2018 → 9 Aug 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- The role of cytopathology in the management of patients with pancreatic tumours - special focus on neuroendocrine tumoursFrom15 Jun 2017 → 17 Sep 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Pancreatic cancer: study of tumor biology and EMT with testing of corresponding drugs in a relevant pre-clinical modelFrom1 Oct 2016 → 30 Sep 2018Funding: BOF - Other initiatives
Publications
1 - 10 of 262
- Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality.(2023)
Authors: Adrianus van Pelt, Rita Derua, Liesbeth Guffens, Veerle Janssens, Chris Verslype
Pages: 317 - The effect of hypoxia on Daphnia magna performance and its associated microbial and bacterioplankton community: A scope for phenotypic plasticity and microbiome community interactions upon environmental stress?(2023)
Authors: Manon Coone, Chris Verslype, Ellen Decaestecker
- 18F-AlF-NOTA-Octreotide Outperforms 68Ga-DOTATATE/NOC PET in Neuroendocrine Tumor Patients: Results from a Prospective, Multicenter Study.(2023)
Authors: Elin Pauwels, Frederik Cleeren, Michel Koole, Jeroen Dekervel, Annouschka Laenen, Paul Clement, Chris Verslype, Guy Bormans, Christophe Deroose
Pages: 632 - 638 - Transition from laparoscopic to robotic liver surgery: clinical outcomes, learning curve effect, and cost-effectiveness(2023)
Authors: Hans Pottel, Chris Verslype
Pages: 79 - 88 - Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma(2023)
Authors: Lisa Kinget, Sarah Cappuyns, Chris Verslype, Benoit Beuselinck, Jeroen Dekervel
- Closing spontaneous portosystemic shunts in cirrhosis: Does it make sense? Does it work? What does it take?(2022)
Authors: Wim Laleman, Emma Vanderschueren, Chris Verslype, Geert Maleux
- A Comparative Study of an Integrated Ultrasonic/Bipolar Sealing Device Versus an Articulating Bipolar Sealing Device for Laparoscopic Liver Surgery(2022)
Authors: Hans Pottel, Chris Verslype
Pages: 2963 - 2972 - Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib(2022)
Authors: Chris Verslype
Pages: 4716 - 4726 - Long-term outcome of liver transplantation for unresectable liver metastases from neuroendocrine neoplasms: a Belgian retrospective multi-centre study(2022)
Authors: Jacques Pirenne, Chris Verslype
Pages: 13 - 13 - Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial(2022)
Authors: Chris Verslype
Pages: 2547 - 2554